CLPA, LLY to conduct Phase I studies

Cell Pathways and Eli Lilly will conduct Phase I studies to examine the combination of CLPA's Aptosyn exisulind oral sulfone metabolite of sulindac that augments apoptosis and LLY's Gemzar gemcitabine...